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macoeconomic evidence of TNF inhibitors in AS and to provide
a critique of the methodology using Drummond’s 10-point
checklist. METHODS: A systematic literature search was con-
ducted by one researcher among publications in peer-reviewed
journals from January 2000 to April 2006 through electronic
databases (Medline, Embase, and Cochrane Database). Only
studies that provided economic evaluations of TNF inhibitors in
AS were included in the review. RESULTS: The search yielded a
total of eight cost studies. Only four met study inclusion crite-
ria. Three of the four studies were cost-effectiveness analysis and
two of the four compared etanercept and inﬂiximab in patients
with AS. The analytical time frame ranged from one year to 30
years. Costs and effects were appropriately discounted and 
sensitivity analysis was conducted to test the robustness of 
the model assumptions. Outcomes were presented as cost per
quality-adjusted life years (QALYs) or cost per Assessment in
Ankylosing Spondylitis Response Criteria. The incremental cost-
utility ratio of etanercept or inﬂiximab varied between US
$50,000–$250,000 per QALY when compared with usual care.
CONCLUSION: The costs per QALY ratios for the TNF
inhibitors seem to be a little higher than the normally accepted
societal thresholds ($50,000/QALY). The heterogeneity in the
cost-effectiveness results could be due to factors like patient
demographics, funding source and methodological variables.
Nonetheless, TNF inhibitors are a valuable treatment option and
further pharmacoeconomic analyses need be conducted to fully
evaluate their potential in patients with AS.
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OBJECTIVES: To assess the utilization patterns and costs for
health care services for chronic arthritis treatment among chil-
dren and adolescents enrolled in a state Medicaid program.
METHODS: A cross-sectional, descriptive analysis of a state
Medicaid administrative claims dataset was conducted. Medical
services claims with a primary diagnosis code for rheumatic dis-
eases (ICD-9-CM 696.0, 695.4, 710.X, 714.0, 714.2, 714.3X,
and 720.X) during calendar year 2003 for recipients under 21
years of age were extracted. Prescription medication claims were
extracted using de-identiﬁed unique recipient numbers obtained
from medical services claims. Prevalence and medical services use
rates were calculated by demographic categories. Costs were
reported from the perspective of Medicaid. RESULTS: There
were 171 children and adolescents who used medical services for
care of chronic arthritis, at an overall rate of 0.8/1000 recipi-
ents. The highest rates by demographic groups occurred among
females (1.0/1000), whites (0.9/1000), and recipients between
15–20 years of age (1.9/1000). Ofﬁce visits accounted for the
majority of medical services utilized (99%), at a rate of 3.4
visits/1000 recipients. Medicaid paid approximately $415/child
and adolescent recipient for chronic arthritis-related medical ser-
vices during the year. Dollars paid for ofﬁce visits accounted for
85% of the medical services costs at an average cost of $86 per
visit. A majority of the sample (63%) had a diagnosis for
rheumatoid arthritis (RA)/juvenile rheumatoid arthritis (JRA).
Among these children and adolescents, 62% had at least one pre-
scription claim for a narcotic analgesic, NSAID, oral steroid,
DMARD, or biologic agent at an average cost of $74/claim.
CONCLUSION: The prevalence and medical services utilization
patterns for chronic arthritis among children and adolescent
recipients in this State Medicaid population differed by demo-
graphic characteristics. Ofﬁce visits accounted for a majority of
medical services use and dollars. Most of the children and ado-
lescents with chronic arthritis had a diagnosis for RA/JRA.
PAR15
USING MIXED TREATMENT COMPARISONS AND META-
REGRESSION TO PERFORM INDIRECT COMPARISONS TO
ESTIMATE THE EFFICACY OF BIOLOGIC TREATMENTS IN
RHEUMATOID ARTHRITIS
Nixon R1, Bansback N2, Brennan A3
1MRC Biostatistics Unit, Cambridge, Cambridgeshire, UK, 2Centre for
Health Evaluation and Outcome Sciences,Vancouver, BC, Canada,
3Shefﬁeld School of Health and Related Research, Shefﬁeld, South
Yourkshire, UK
OBJECTIVES: Mixed treatment comparison is a generalisation
of meta-analysis. Instead of the same treatment for a disease
being tested in a number of studies, a number of different inter-
ventions are considered. Meta-regression is also a generalisation
of meta-analysis which explains the heterogeneity between the
treatment effects in the studies by regressing on study level
covariables. Our focus is where there are several different treat-
ments considered in a number of studies, and where differences
in efﬁcacy can be explained by differences in the study settings.
METHODS: We develop methods for simultaneously compar-
ing several treatments and adjusting for study level covariables
by combining ideas from mixed treatment comparisons and
meta-regression. We use a case study from rheumatoid arthritis.
We identiﬁed relevant trials of biologic verses standard therapy
or placebo and extracted the doses, comparators and patient
baseline characteristics. Efﬁcacy is measured using the log odds
ratio of achieving ACR50 responder status at 6 months. A
random-effects meta-regression model is ﬁtted which adjusts the
log odds ratio of an ACR50 response if treated with a biologic
therapy compared to placebo for study level prognostic factors.
The logit probability of a response is regressed onto a treatment
indicator and prognostic covariables. A different random effect
distribution on the log odds ratios is allowed for each different
treatment. This enables the odds ratio for each treatment to be
found as a function of the prognostic factors. RESULTS: The
apparent differences in the randomised trials between TNF
antagonists biologics are explained by differences in prognostic
factors and the analysis suggest that these drugs as a class are
not different from each other. CONCLUSION: We deﬁne a
methodology for combining meta-regression techniques with
ideas from mixed treatment comparisons. This allows different
treatments for the same condition to be compared whilst adjust-
ing for difference in the study populations.
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OBJECTIVES: To evaluate switching patterns among anti-TNFs
in rheumatoid arthritis (RA) patients. METHODS: A retrospec-
tive study utilizing the PharMetrics managed-care claims data-
base was conducted. The ﬁrst anti-TNF encounter among RA
patients between January 1, 2001 and January 1, 2004 was iden-
tiﬁed. Patients were required to have a minimum of 12-months
of continuous plan eligibility prior to and following their index
date. Three mutually exclusive cohorts were developed based on
their index biologic therapy (inﬂiximab, etanercept and adali-
mumab) plus methotrexate (MTX). The rates of switching and
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time before switching were examined. Descriptive and Chi-
Square statistical analyses were conducted to determine if dif-
ferences existed among the three cohorts. RESULTS: A total of
1242 patients were analyzed: 490 (39.4%) inﬂiximab plus MTX;
607 (48.9%) etanercept plus MTX; and 145 (11.7%) adali-
mumab plus MTX. Over two-thirds of the patients were female
and the mean age was 50.0 years. The Charlson Co-morbidity
Index and disease staging were similar among the three cohorts.
During the 12 months follow-up, 39 patients (7.9%) in the inﬂix-
imab plus MTX cohort switched compared to 72 patients
(11.9%) in the etanercept group and 23 patients (15.9%) in the
adalimumab group. Chi-Square analyses indicated the differ-
ences were statistically signiﬁcant (p < 0.05) as compared to the
inﬂiximab plus MTX cohort. The inﬂiximab group had an
average time of 195.9 days before switching, compared to 183.1
days in the etanercept group, and 165.3 in the adalimumab
group; this was not statistically signiﬁcant. CONCLUSION: The
rate of switching and time before switching are important mea-
sures of the effectiveness of RA treatment in real world practice.
This study found that inﬂiximab plus MTX is associated with a
longer time before switching and a signiﬁcantly lower switching
rate, as compared to the other anti-TNFs. Further studies are
needed to evaluate the impact of switching on clinical and eco-
nomic outcomes.
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OBJECTIVES: To evaluate persistence of anti-TNF treatment
among rheumatoid arthritis (RA) patients utilizing a managed
care database. METHODS: A retrospective study utilizing the
PharMetrics managed care claims database was conducted. The
ﬁrst anti-TNF (inﬂiximab, etanercept, or adalimumab) encounter
(index date) among RA patients between January 1, 2001 and
January 1, 2004 was identiﬁed. Patients were required to have a
minimum of 12-months of continuous plan eligibility prior to
and following their index biologic date. Three mutually exclu-
sive cohorts were developed based on their index biologic; inﬂix-
imab plus methotrexate (MTX); etanercept plus MTX; and
adalimumab plus MTX. Anti-TNF persistence (%) was deﬁned
as the number of days between the ﬁrst biologic prescription and
their last biologic encounter, divided by 365 and multiplied by
100. Both univariate and multivariate analyses were applied to
determine if differences in persistence existed between the three
cohorts. RESULTS: A total of 1242 patients were analyzed con-
sisting of 490 (39.4%) inﬂiximab plus MTX; 607 (48.9%) etan-
ercept plus MTX; and 145 (11.7%) adalimumab plus MTX.
Over two-thirds of the patients were female and the mean age
was 50.0 years. The Charlson Co-morbidity Index and disease
staging were consistent among the three cohorts. The inﬂiximab
plus MTX cohort was more persistent [78.0% than the other 2
cohorts (etanercept plus MTX 73.6% and adalimumab plus
MTX 70.8%)] and was statistically signiﬁcant (p < 0.05). After
adjusting for potential confounding variables (age, gender,
Charlson co-morbidity index and disease severity), inﬂiximab
patients had 5.4% more persistence than etanercept (p < 0.01),
and 7.0% more than the adalimumab group (p < 0.05). Etaner-
cept patients were more persistent than the adalimumab group,
however, the difference was not signiﬁcant (p > 0.05). CON-
CLUSION: These results indicate that patients on inﬂiximab plus
MTX are more persistent with anti-TNF therapy, compared to
other anti-TNFs. Further studies are needed to evaluate the
impact of persistence on clinical outcomes.
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OBJECTIVES: To compare dosing stability and dose changes,
through a retrospective database analysis, for rheumatoid arthri-
tis (RA) patients taking inﬂiximab over ﬁve years. METHODS:
We utilized medical and pharmacy claims data from the Medstat
MarketScan database. The sample consisted of “new starts” for
inﬂiximab users in the commercial and Medicare population: (a)
with a diagnosis of Rheumatoid Arthritis (RA) (ICD-9 714.xx),
(b) who had at least three documented administrations of inﬂix-
imab between 1999 and 2005, (c) who had no prescription
history for any TNF blocker for a 6 month period prior to the
index infusion, and, (d) who were continuously enrolled for a
minimum of 365 days after their index infusion. We examined
the proportion of inﬂiximab users who showed an increase,
decrease, or no change in dose over time in both groups.
RESULTS: Medicare inﬂiximab users (n = 729) were older (mean
age = 73 years) with higher co-morbid scores (mean score = 9.71)
than commercial users (n = 1903, mean age = 50 years, mean
score = 3.83). Following the index infusion, 30.4% of commer-
cial and 17.7% of Medicare users showed no change; 24.6% of
commercial and 43.1% of Medicare users showed a decrease;
and 44.9% of commercial and 39.2% of Medicare members
showed an increase in their dose. For the ﬁve-year period, the
total average dose change between the ﬁrst and last infusion was
24 mg for the Medicare group and 44 mg for the commercial
group. Medicare members also had a lower starting dose than
commercial members (328 mg vs. 366 mg). CONCLUSION:
This study demonstrates that there is dose stability in RA
patients treated with inﬂiximab, as the dose changed on average,
by less than 3% per year over the ﬁve-year period. Further
research is needed to evaluate the impact of dose changes on clin-
ical and economic outcomes.
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OBJECTIVES: Clinicians have long observed a link between
physical pain and a compromised quality of life among the clin-
ical population. However, little is known about the association
between arthritis and the quality of life in the general popula-
tion. This study is designed to identify the impact of arthritis on
the quality of life among adults. METHODS: The Behavioral
Risk Factor Surveillance System (BRFSS) is a state-based,
random-digit-dialed telephone survey of the non-institutional-
ized U.S. population aged 18 years and older. The Ohio BRFSS-
2005 survey, containing 7498 adults was analyzed. As a measure
of Health–Related Quality of Life, the number of “unhealthy
days” during the preceding 30 days was surveyed. All informa-
tion was self-reported. RESULTS: Approximately the same pro-
portion of adults in different age groups experienced at least one
physical unhealthy day in the general adult population (35.6%,
18–44 years old; 37.3%, 45–64 years old; 36.3%, 65 years old
